APO Research
Talk to an analyst

APO RESEARCH · REPORT

Renal Cell Cacinoma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Renal Cell Cacinoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchRenal Cell Cacinoma Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Renal Cell Cacinoma Drugs Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Renal Cell Cacinoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Renal Cell Cacinoma Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Renal Cell Cacinoma Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Renal Cell Cacinoma Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Renal Cell Cacinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Renal Cell Cacinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Renal Cell Cacinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Renal Cell Cacinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Renal Cell Cacinoma Drugs include Eisai, Merck & Co., Inc., TVAX Biomedical, TRACON Pharmaceuticals, Rexahn Pharmaceuticals, Immatics Biotechnologies, Genentech, Exelixis Inc and Cerulean Pharma Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Renal Cell Cacinoma Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Renal Cell Cacinoma Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Renal Cell Cacinoma Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Renal Cell Cacinoma Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Renal Cell Cacinoma Drugs Segment by Company

Eisai

Merck & Co., Inc.

TVAX Biomedical

TRACON Pharmaceuticals

Rexahn Pharmaceuticals

Immatics Biotechnologies

Genentech

Exelixis Inc

Cerulean Pharma Inc

Celldex Therapeutics

Bristol-Myers Squibb

Bionomics

AVEO Oncology

Argus Therapeutics, Inc.

Acceleron

Renal Cell Cacinoma Drugs Segment by Type

Afinitor(Everolimus)

Torisel(Temsirolimus)

Sutent(Sunitinib)

Votrient(Pazopanib)

Nexavar(Sorafenib)

Inlyta(Axitinib)

Avastin(Bevacizumab)

Proleukin(Aldesleukin)

Renal Cell Cacinoma Drugs Segment by Application

Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)

Tubulocystic Renal Cell Carcinoma

Thyroid-Like Follicular Renal Cell Carcinoma

Multilocular Cystic Clear Cell Renal Cell Carcinoma

Others

Renal Cell Cacinoma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Renal Cell Cacinoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Renal Cell Cacinoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Renal Cell Cacinoma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Renal Cell Cacinoma Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Renal Cell Cacinoma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Renal Cell Cacinoma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Renal Cell Cacinoma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Renal Cell Cacinoma Drugs Industry Trends Table 2. Renal Cell Cacinoma Drugs Industry Drivers Table 3. Renal Cell Cacinoma Drugs Industry Opportunities and Challenges Table 4. Renal Cell Cacinoma Drugs Industry Restraints Table 5. Global Renal Cell Cacinoma Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Renal Cell Cacinoma Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Renal Cell Cacinoma Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Renal Cell Cacinoma Drugs Sales Market Share by Manufacturers Table 9. Global Renal Cell Cacinoma Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Renal Cell Cacinoma Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Renal Cell Cacinoma Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Renal Cell Cacinoma Drugs Manufacturers, Product Type & Application Table 13. Global Renal Cell Cacinoma Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Renal Cell Cacinoma Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Afinitor(Everolimus) Table 17. Major Manufacturers of Torisel(Temsirolimus) Table 18. Major Manufacturers of Sutent(Sunitinib) Table 19. Major Manufacturers of Votrient(Pazopanib) Table 20. Major Manufacturers of Nexavar(Sorafenib) Table 21. Major Manufacturers of Inlyta(Axitinib) Table 22. Major Manufacturers of Avastin(Bevacizumab) Table 23. Major Manufacturers of Proleukin(Aldesleukin) Table 24. Global Renal Cell Cacinoma Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Renal Cell Cacinoma Drugs Sales by Type (2021-2026) & (W Units) Table 26. Global Renal Cell Cacinoma Drugs Sales by Type (2027-2032) & (W Units) Table 27. Global Renal Cell Cacinoma Drugs Sales Market Share by Type (2021-2026) Table 28. Global Renal Cell Cacinoma Drugs Sales Market Share by Type (2027-2032) Table 29. Global Renal Cell Cacinoma Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 30. Global Renal Cell Cacinoma Drugs Revenue by Type (2021-2026) & (W Units) Table 31. Global Renal Cell Cacinoma Drugs Revenue by Type (2027-2032) & (W Units) Table 32. Global Renal Cell Cacinoma Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Renal Cell Cacinoma Drugs Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) Table 35. Major Manufacturers of Tubulocystic Renal Cell Carcinoma Table 36. Major Manufacturers of Thyroid-Like Follicular Renal Cell Carcinoma Table 37. Major Manufacturers of Multilocular Cystic Clear Cell Renal Cell Carcinoma Table 38. Major Manufacturers of Others Table 39. Global Renal Cell Cacinoma Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Renal Cell Cacinoma Drugs Sales by Application (2021-2026) & (W Units) Table 41. Global Renal Cell Cacinoma Drugs Sales by Application (2027-2032) & (W Units) Table 42. Global Renal Cell Cacinoma Drugs Sales Market Share by Application (2021-2026) Table 43. Global Renal Cell Cacinoma Drugs Sales Market Share by Application (2027-2032) Table 44. Global Renal Cell Cacinoma Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 45. Global Renal Cell Cacinoma Drugs Revenue by Application (2021-2026) & (W Units) Table 46. Global Renal Cell Cacinoma Drugs Revenue by Application (2027-2032) & (W Units) Table 47. Global Renal Cell Cacinoma Drugs Revenue Market Share by Application (2021-2026) Table 48. Global Renal Cell Cacinoma Drugs Revenue Market Share by Application (2027-2032) Table 49. Global Renal Cell Cacinoma Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 50. Global Renal Cell Cacinoma Drugs Sales by Region (2021-2026) & (W Units) Table 51. Global Renal Cell Cacinoma Drugs Sales Market Share by Region (2021-2026) Table 52. Global Renal Cell Cacinoma Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 53. Global Renal Cell Cacinoma Drugs Sales Forecasted Market Share by Region (2027-2032) Table 54. North America Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. North America Renal Cell Cacinoma Drugs Sales by Country (2021-2026) & (W Units) Table 56. North America Renal Cell Cacinoma Drugs Sales by Country (2027-2032) & (W Units) Table 57. Europe Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Europe Renal Cell Cacinoma Drugs Sales by Country (2021-2026) & (W Units) Table 59. Europe Renal Cell Cacinoma Drugs Sales by Country (2027-2032) & (W Units) Table 60. Asia Pacific Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. Asia Pacific Renal Cell Cacinoma Drugs Sales by Country (2021-2026) & (W Units) Table 62. Asia Pacific Renal Cell Cacinoma Drugs Sales by Country (2027-2032) & (W Units) Table 63. South America, Middle East and Africa Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 64. South America, Middle East and Africa Renal Cell Cacinoma Drugs Sales by Country (2021-2026) & (W Units) Table 65. South America, Middle East and Africa Renal Cell Cacinoma Drugs Sales by Country (2027-2032) & (W Units) Table 66. Global Renal Cell Cacinoma Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 67. Global Renal Cell Cacinoma Drugs Revenue by Region (2021-2026) & (US$ Million) Table 68. Global Renal Cell Cacinoma Drugs Revenue by Region (2027-2032) & (US$ Million) Table 69. Global Renal Cell Cacinoma Drugs Revenue Market Share by Region (2021-2026) Table 70. Global Renal Cell Cacinoma Drugs Revenue Market Share by Region (2027-2032) Table 71. Eisai Company Information Table 72. Eisai Business Overview Table 73. Eisai Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Eisai Renal Cell Cacinoma Drugs Product Portfolio Table 75. Eisai Recent Development Table 76. Merck & Co., Inc. Company Information Table 77. Merck & Co., Inc. Business Overview Table 78. Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Merck & Co., Inc. Renal Cell Cacinoma Drugs Product Portfolio Table 80. Merck & Co., Inc. Recent Development Table 81. TVAX Biomedical Company Information Table 82. TVAX Biomedical Business Overview Table 83. TVAX Biomedical Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. TVAX Biomedical Renal Cell Cacinoma Drugs Product Portfolio Table 85. TVAX Biomedical Recent Development Table 86. TRACON Pharmaceuticals Company Information Table 87. TRACON Pharmaceuticals Business Overview Table 88. TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Product Portfolio Table 90. TRACON Pharmaceuticals Recent Development Table 91. Rexahn Pharmaceuticals Company Information Table 92. Rexahn Pharmaceuticals Business Overview Table 93. Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Product Portfolio Table 95. Rexahn Pharmaceuticals Recent Development Table 96. Immatics Biotechnologies Company Information Table 97. Immatics Biotechnologies Business Overview Table 98. Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Immatics Biotechnologies Renal Cell Cacinoma Drugs Product Portfolio Table 100. Immatics Biotechnologies Recent Development Table 101. Genentech Company Information Table 102. Genentech Business Overview Table 103. Genentech Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Genentech Renal Cell Cacinoma Drugs Product Portfolio Table 105. Genentech Recent Development Table 106. Exelixis Inc Company Information Table 107. Exelixis Inc Business Overview Table 108. Exelixis Inc Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Exelixis Inc Renal Cell Cacinoma Drugs Product Portfolio Table 110. Exelixis Inc Recent Development Table 111. Cerulean Pharma Inc Company Information Table 112. Cerulean Pharma Inc Business Overview Table 113. Cerulean Pharma Inc Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Cerulean Pharma Inc Renal Cell Cacinoma Drugs Product Portfolio Table 115. Cerulean Pharma Inc Recent Development Table 116. Celldex Therapeutics Company Information Table 117. Celldex Therapeutics Business Overview Table 118. Celldex Therapeutics Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Celldex Therapeutics Renal Cell Cacinoma Drugs Product Portfolio Table 120. Celldex Therapeutics Recent Development Table 121. Bristol-Myers Squibb Company Information Table 122. Bristol-Myers Squibb Business Overview Table 123. Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Bristol-Myers Squibb Renal Cell Cacinoma Drugs Product Portfolio Table 125. Bristol-Myers Squibb Recent Development Table 126. Bionomics Company Information Table 127. Bionomics Business Overview Table 128. Bionomics Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Bionomics Renal Cell Cacinoma Drugs Product Portfolio Table 130. Bionomics Recent Development Table 131. AVEO Oncology Company Information Table 132. AVEO Oncology Business Overview Table 133. AVEO Oncology Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. AVEO Oncology Renal Cell Cacinoma Drugs Product Portfolio Table 135. AVEO Oncology Recent Development Table 136. Argus Therapeutics, Inc. Company Information Table 137. Argus Therapeutics, Inc. Business Overview Table 138. Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Product Portfolio Table 140. Argus Therapeutics, Inc. Recent Development Table 141. Acceleron Company Information Table 142. Acceleron Business Overview Table 143. Acceleron Renal Cell Cacinoma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Acceleron Renal Cell Cacinoma Drugs Product Portfolio Table 145. Acceleron Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Renal Cell Cacinoma Drugs Distributors List Table 149. Renal Cell Cacinoma Drugs Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Renal Cell Cacinoma Drugs Product Image Figure 2. Global Renal Cell Cacinoma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Renal Cell Cacinoma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Renal Cell Cacinoma Drugs Sales (2021-2032) & (W Units) Figure 5. Global Renal Cell Cacinoma Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Renal Cell Cacinoma Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Afinitor(Everolimus) Image Figure 9. Torisel(Temsirolimus) Image Figure 10. Sutent(Sunitinib) Image Figure 11. Votrient(Pazopanib) Image Figure 12. Nexavar(Sorafenib) Image Figure 13. Inlyta(Axitinib) Image Figure 14. Avastin(Bevacizumab) Image Figure 15. Proleukin(Aldesleukin) Image Figure 16. Global Renal Cell Cacinoma Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Renal Cell Cacinoma Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Renal Cell Cacinoma Drugs Sales Market Share by Type (2021-2032) Figure 19. Global Renal Cell Cacinoma Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Renal Cell Cacinoma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Renal Cell Cacinoma Drugs Revenue Market Share by Type (2021-2032) Figure 22. Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) Image Figure 23. Tubulocystic Renal Cell Carcinoma Image Figure 24. Thyroid-Like Follicular Renal Cell Carcinoma Image Figure 25. Multilocular Cystic Clear Cell Renal Cell Carcinoma Image Figure 26. Others Image Figure 27. Global Renal Cell Cacinoma Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Renal Cell Cacinoma Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 29. Global Renal Cell Cacinoma Drugs Sales Market Share by Application (2021-2032) Figure 30. Global Renal Cell Cacinoma Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 31. Global Renal Cell Cacinoma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 32. Global Renal Cell Cacinoma Drugs Revenue Market Share by Application (2021-2032) Figure 33. North America Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 34. North America Renal Cell Cacinoma Drugs Sales Market Share by Country (2021-2032) Figure 35. U.S. Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Canada Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Mexico Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Europe Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Europe Renal Cell Cacinoma Drugs Sales Market Share by Country (2021-2032) Figure 40. Germany Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 41. France Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 42. U.K. Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Italy Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Netherlands Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Asia Pacific Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Asia Pacific Renal Cell Cacinoma Drugs Sales Market Share by Country (2021-2032) Figure 47. China Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Japan Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South Korea Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Southeast Asia Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 51. India Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Australia Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South America, Middle East and Africa Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 54. South America, Middle East and Africa Renal Cell Cacinoma Drugs Sales Market Share by Country (2021-2032) Figure 55. Brazil Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 56. South Africa Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Saudi Arabia Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Turkey Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Argentina Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 60. UAE Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Egypt Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 62. Chile Renal Cell Cacinoma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 63. Global Renal Cell Cacinoma Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Global Renal Cell Cacinoma Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 65. North America Renal Cell Cacinoma Drugs Revenue (2021-2032) & (US$ Million) Figure 66. North America Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Europe Renal Cell Cacinoma Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Europe Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Asia-Pacific Renal Cell Cacinoma Drugs Revenue (2021-2032) & (US$ Million) Figure 70. Asia-Pacific Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. South America, Middle East and Africa Renal Cell Cacinoma Drugs Revenue (2021-2032) & (US$ Million) Figure 72. South America, Middle East and Africa Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 73. Renal Cell Cacinoma Drugs Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Renal Cell Cacinoma Drugs Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Afinitor(Everolimus)
  • Torisel(Temsirolimus)
  • Sutent(Sunitinib)
  • Votrient(Pazopanib)
  • Nexavar(Sorafenib)
  • Inlyta(Axitinib)
  • Avastin(Bevacizumab)
  • Proleukin(Aldesleukin)
Applications
  • Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
  • Tubulocystic Renal Cell Carcinoma
  • Thyroid-Like Follicular Renal Cell Carcinoma
  • Multilocular Cystic Clear Cell Renal Cell Carcinoma
  • Others
Companies covered
  • Eisai
  • Merck & Co., Inc.
  • TVAX Biomedical
  • TRACON Pharmaceuticals
  • Rexahn Pharmaceuticals
  • Immatics Biotechnologies
  • Genentech
  • Exelixis Inc
  • Cerulean Pharma Inc
  • Celldex Therapeutics
  • Bristol-Myers Squibb
  • Bionomics
  • AVEO Oncology
  • Argus Therapeutics, Inc.
  • Acceleron

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Renal Cell Cacinoma Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Renal Cell Cacinoma Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Renal Cell Cacinoma Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Renal Cell Cacinoma Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Renal Cell Cacinoma Drugs Market Dynamics
  1. 2.1 Renal Cell Cacinoma Drugs Industry Trends
  2. 2.2 Renal Cell Cacinoma Drugs Industry Drivers
  3. 2.3 Renal Cell Cacinoma Drugs Industry Opportunities and Challenges
  4. 2.4 Renal Cell Cacinoma Drugs Industry Restraints
3 Renal Cell Cacinoma Drugs Market by Manufacturers
  1. 3.1 Global Renal Cell Cacinoma Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Renal Cell Cacinoma Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Renal Cell Cacinoma Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Renal Cell Cacinoma Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Renal Cell Cacinoma Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Renal Cell Cacinoma Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Renal Cell Cacinoma Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Renal Cell Cacinoma Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Renal Cell Cacinoma Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Renal Cell Cacinoma Drugs Tier 1, Tier 2, and Tier 3
4 Renal Cell Cacinoma Drugs Market by Type
  1. 4.1 Renal Cell Cacinoma Drugs Type Introduction
  2. 4.1.1 Afinitor(Everolimus)
  3. 4.1.2 Torisel(Temsirolimus)
  4. 4.1.3 Sutent(Sunitinib)
  5. 4.1.4 Votrient(Pazopanib)
  6. 4.1.5 Nexavar(Sorafenib)
  7. 4.1.6 Inlyta(Axitinib)
  8. 4.1.7 Avastin(Bevacizumab)
  9. 4.1.8 Proleukin(Aldesleukin)
  10. 4.2 Global Renal Cell Cacinoma Drugs Sales by Type
  11. 4.2.1 Global Renal Cell Cacinoma Drugs Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Renal Cell Cacinoma Drugs Sales by Type (2021-2032)
  13. 4.2.3 Global Renal Cell Cacinoma Drugs Sales Market Share by Type (2021-2032)
  14. 4.3 Global Renal Cell Cacinoma Drugs Revenue by Type
  15. 4.3.1 Global Renal Cell Cacinoma Drugs Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Renal Cell Cacinoma Drugs Revenue by Type (2021-2032)
  17. 4.3.3 Global Renal Cell Cacinoma Drugs Revenue Market Share by Type (2021-2032)
5 Renal Cell Cacinoma Drugs Market by Application
  1. 5.1 Renal Cell Cacinoma Drugs Application Introduction
  2. 5.1.1 Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
  3. 5.1.2 Tubulocystic Renal Cell Carcinoma
  4. 5.1.3 Thyroid-Like Follicular Renal Cell Carcinoma
  5. 5.1.4 Multilocular Cystic Clear Cell Renal Cell Carcinoma
  6. 5.1.5 Others
  7. 5.2 Global Renal Cell Cacinoma Drugs Sales by Application
  8. 5.2.1 Global Renal Cell Cacinoma Drugs Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Renal Cell Cacinoma Drugs Sales by Application (2021-2032)
  10. 5.2.3 Global Renal Cell Cacinoma Drugs Sales Market Share by Application (2021-2032)
  11. 5.3 Global Renal Cell Cacinoma Drugs Revenue by Application
  12. 5.3.1 Global Renal Cell Cacinoma Drugs Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Renal Cell Cacinoma Drugs Revenue by Application (2021-2032)
  14. 5.3.3 Global Renal Cell Cacinoma Drugs Revenue Market Share by Application (2021-2032)
6 Global Renal Cell Cacinoma Drugs Sales by Region
  1. 6.1 Global Renal Cell Cacinoma Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Renal Cell Cacinoma Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Renal Cell Cacinoma Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Renal Cell Cacinoma Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Renal Cell Cacinoma Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Renal Cell Cacinoma Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Renal Cell Cacinoma Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Renal Cell Cacinoma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Renal Cell Cacinoma Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Renal Cell Cacinoma Drugs Revenue by Region
  1. 7.1 Global Renal Cell Cacinoma Drugs Revenue by Region
  2. 7.1.1 Global Renal Cell Cacinoma Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Renal Cell Cacinoma Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Renal Cell Cacinoma Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Renal Cell Cacinoma Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Renal Cell Cacinoma Drugs Revenue (2021-2032)
  8. 7.2.2 North America Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Renal Cell Cacinoma Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Renal Cell Cacinoma Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Renal Cell Cacinoma Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Renal Cell Cacinoma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Renal Cell Cacinoma Drugs Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Renal Cell Cacinoma Drugs Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 TVAX Biomedical
  14. 8.3.1 TVAX Biomedical Company Information
  15. 8.3.2 TVAX Biomedical Business Overview
  16. 8.3.3 TVAX Biomedical Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 TVAX Biomedical Renal Cell Cacinoma Drugs Product Portfolio
  18. 8.3.5 TVAX Biomedical Recent Developments
  19. 8.4 TRACON Pharmaceuticals
  20. 8.4.1 TRACON Pharmaceuticals Company Information
  21. 8.4.2 TRACON Pharmaceuticals Business Overview
  22. 8.4.3 TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Product Portfolio
  24. 8.4.5 TRACON Pharmaceuticals Recent Developments
  25. 8.5 Rexahn Pharmaceuticals
  26. 8.5.1 Rexahn Pharmaceuticals Company Information
  27. 8.5.2 Rexahn Pharmaceuticals Business Overview
  28. 8.5.3 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Product Portfolio
  30. 8.5.5 Rexahn Pharmaceuticals Recent Developments
  31. 8.6 Immatics Biotechnologies
  32. 8.6.1 Immatics Biotechnologies Company Information
  33. 8.6.2 Immatics Biotechnologies Business Overview
  34. 8.6.3 Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Immatics Biotechnologies Renal Cell Cacinoma Drugs Product Portfolio
  36. 8.6.5 Immatics Biotechnologies Recent Developments
  37. 8.7 Genentech
  38. 8.7.1 Genentech Company Information
  39. 8.7.2 Genentech Business Overview
  40. 8.7.3 Genentech Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genentech Renal Cell Cacinoma Drugs Product Portfolio
  42. 8.7.5 Genentech Recent Developments
  43. 8.8 Exelixis Inc
  44. 8.8.1 Exelixis Inc Company Information
  45. 8.8.2 Exelixis Inc Business Overview
  46. 8.8.3 Exelixis Inc Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Exelixis Inc Renal Cell Cacinoma Drugs Product Portfolio
  48. 8.8.5 Exelixis Inc Recent Developments
  49. 8.9 Cerulean Pharma Inc
  50. 8.9.1 Cerulean Pharma Inc Company Information
  51. 8.9.2 Cerulean Pharma Inc Business Overview
  52. 8.9.3 Cerulean Pharma Inc Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cerulean Pharma Inc Renal Cell Cacinoma Drugs Product Portfolio
  54. 8.9.5 Cerulean Pharma Inc Recent Developments
  55. 8.10 Celldex Therapeutics
  56. 8.10.1 Celldex Therapeutics Company Information
  57. 8.10.2 Celldex Therapeutics Business Overview
  58. 8.10.3 Celldex Therapeutics Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Celldex Therapeutics Renal Cell Cacinoma Drugs Product Portfolio
  60. 8.10.5 Celldex Therapeutics Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Bionomics
  68. 8.12.1 Bionomics Company Information
  69. 8.12.2 Bionomics Business Overview
  70. 8.12.3 Bionomics Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bionomics Renal Cell Cacinoma Drugs Product Portfolio
  72. 8.12.5 Bionomics Recent Developments
  73. 8.13 AVEO Oncology
  74. 8.13.1 AVEO Oncology Company Information
  75. 8.13.2 AVEO Oncology Business Overview
  76. 8.13.3 AVEO Oncology Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AVEO Oncology Renal Cell Cacinoma Drugs Product Portfolio
  78. 8.13.5 AVEO Oncology Recent Developments
  79. 8.14 Argus Therapeutics, Inc.
  80. 8.14.1 Argus Therapeutics, Inc. Company Information
  81. 8.14.2 Argus Therapeutics, Inc. Business Overview
  82. 8.14.3 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Product Portfolio
  84. 8.14.5 Argus Therapeutics, Inc. Recent Developments
  85. 8.15 Acceleron
  86. 8.15.1 Acceleron Company Information
  87. 8.15.2 Acceleron Business Overview
  88. 8.15.3 Acceleron Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Acceleron Renal Cell Cacinoma Drugs Product Portfolio
  90. 8.15.5 Acceleron Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Renal Cell Cacinoma Drugs Value Chain Analysis
  2. 9.1.1 Renal Cell Cacinoma Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Renal Cell Cacinoma Drugs Production Mode & Process
  6. 9.2 Renal Cell Cacinoma Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Renal Cell Cacinoma Drugs Distributors
  9. 9.2.3 Renal Cell Cacinoma Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst